Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines - PubMed (original) (raw)

Comparative Study

Evaluation of pneumococcal polysaccharide immunoassays using a 22F adsorption step with serum samples from infants vaccinated with conjugate vaccines

Jan T Poolman et al. Clin Vaccine Immunol. 2010 Jan.

Abstract

The history of the pneumococcal polysaccharide enzyme-linked immunosorbent assay (ELISA) is characterized by a continuous search for increased specificity. A third-generation ELISA that uses 22F polysaccharide inhibition has increased the specificity of the assay, particularly at low antibody concentrations. The present work compared various 22F ELISAs and non-22F ELISAs. The comparisons involved three different laboratories, including a WHO reference laboratory, and included sera from subjects from different geographic areas immunized with different pneumococcal conjugate vaccines, including the licensed 7-valent Prevenar vaccine and the 10-valent Synflorix vaccine. All comparisons led to the same conclusion that the threshold defined as 0.35 microg/ml for the WHO non-22F ELISA is lower when any 22F ELISA is used. The use of highly purified polysaccharides for coating further improved the specificity of the assay. In conclusion, we confirm that the 22F ELISA can be recommended as a reference method for the determination of antibodies against pneumococcal polysaccharides.

PubMed Disclaimer

Figures

FIG. 1.

FIG. 1.

Aggregate reverse cumulative distribution curves of anti-PS IgG concentrations measured in the sera of infants from Europe and Latin America after immunization with a pneumococcal conjugate vaccine for comparison of the GSK 22F ELISA and the WHO non-22F ELISA (study A). Aggregate reverse cumulative distribution curves were plotted by using the concentrations of antibodies against pneumococcal serotype 4, 6B, 9V, 14, 18C, 19F, and 23F polysaccharides.

FIG. 2.

FIG. 2.

Aggregate reverse cumulative distribution curves of anti-PS IgG concentrations measured in pediatric sera after immunization with the Prevenar or the Meningitec vaccine by using the GSK 22F ELISA (study B).

FIG. 3.

FIG. 3.

Aggregate reverse cumulative distribution curves of anti-PS IgG concentrations measured in pediatric sera after immunization with the Prevenar vaccine for comparison of the WHO non-22F ELISA and the WHO 22F ELISA, both of which were performed at ICH, with the GSK 22F ELISA, which was performed at GSK (study C). In addition to our standard comparison of the WHO non-22F ELISA (threshold, 0.35 μg/ml) with the two 22F ELISAs (GSK 22 [dotted lines] and WHO 22F [blue dashed line]), a comparison of the WHO 22F ELISA (by use of a 0.35-μg/ml threshold) and the GSK 22F ELISA was also performed (red dashed line).

FIG. 4.

FIG. 4.

Aggregate reverse cumulative distribution curves of anti-PS IgG concentrations measured in pediatric sera after immunization with a nine-valent pneumococcal conjugate vaccine for comparison of the THL non-22F ELISA and 22F ELISA (study D) by using the concentration of antibodies against pneumococcal serotypes 1, 6B, 14, 19F, and 23F. Data for two groups of vaccinated children, HIV-infected children (n = 20) and non-HIV-infected children (n = 58), were pooled. The data from both groups combined were used to prepare the RCDCs.

FIG. 5.

FIG. 5.

Aggregate reverse cumulative distribution curves of anti-PS IgG concentrations in pediatric sera measured after immunization with the Synflorix or the Prevenar vaccine for comparison of the WHO non-22F ELISA and the GSK 22F ELISA, both of which were performed at the GSK laboratory (study E).

Similar articles

Cited by

References

    1. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards, and Northern California Kaiser Permanente Vaccine Study Center Group. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195. - PubMed
    1. Concepcion, N. F., and C. E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272. - PMC - PubMed
    1. Feavers, I., I. Knezevic, M. Powell, and E. Griffiths. 2009. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 27:3681-3688. - PubMed
    1. Fischer, W., T. Behr, R. Hartmann, J. Peter-Katalinic, and H. Egge. 1993. Teichoic acid and lipoteichoic acid of Streptococcus pneumoniae possess identical chain structures. A reinvestigation of teichoid acid (C polysaccharide). Eur. J. Biochem. 215:851-857. - PubMed
    1. Henckaerts, I., D. Goldblatt, L. Ashton, and J. Poolman. 2006. Critical differences between pneumococcal polysaccharide enzyme-linked immunosorbent assays with and without 22F inhibition at low antibody concentrations in pediatric sera. Clin. Vaccine Immunol. 13:356-360. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources